Showing 2611-2620 of 4112 results for "".
- Does IL-17 Play a Role in Skin Aging?https://practicaldermatology.com/news/does-il-17-play-a-role-in-skin-aging/2461770/Interleukin (IL)-17 may plays a central role in skin aging, according to research from Institute for Research in Biomedicine (IRB Barcelona) in collaboration with the National Center for Genomic Analysis (CNAG). The study, which was led by Dr. Guiomar Solanas, Dr. Salvador Azn
- Crown Laboratories Opens Expanded Production Facilityhttps://practicaldermatology.com/news/crown-laboratories-opens-expanded-production-facility/2461769/Crown Laboratories completed a 60,000-square-foot expansion at its manufacturing complex in Johnson City, Tennessee. A year in the making, the $7.5 million expansion project at Lafe Cox Drive increases manufacturing and warehouse space to support business growth. The appr
- Novartis Premieres New HS Docuseries at Tribeca Film Festivalhttps://practicaldermatology.com/news/novartis-premieres-new-hs-docuseries-at-tribeca-film-festival/2461768/Novartis is launching a new docuseries, "The Beacons: Illuminating HS Stories, in recognition of Hidradenitis Suppurativa (HS) Awareness Week. The series, which will premiere during the 2023 Tribeca Festival in New York, is part of the "Shine 
- FDA Nod for Galderma's Restylane Eyelighthttps://practicaldermatology.com/news/fda-nod-for-galdermas-restylane-eyelight/2461760/The U.S. Food and Drug Administration (FDA) approved Restylane Eyelight, a hyaluronic acid (HA) dermal filler for the correction of undereye hollowing, in adults over the age of 21. Restylane Eyelight is formulated with NASHA Technology, which has a firm gel te
- Scientists Identify Genomic Cause and Potential Treatment for Disabling Pansclerotic Morpheahttps://practicaldermatology.com/news/scientists-identify-genomic-cause-and-potential-treatment-for-disabling-pansclerotic-morphea/2461756/Researchers have identified genomic variants that cause disabling pansclerotic morphea and have found a potential treatment. People with the disorder have an overactive version of a protein called STAT4, which regulates inflammation and wound healing. The work also identified a drug tha
- EULAR News: Tremyfa Data Shows Sustained Improvements in PsAhttps://practicaldermatology.com/news/eular-news-tremyfa-data-showing-sustained-improvements-in-psa/2461755/Tremfya (guselkumab) provides sustainable improvements in all minimal disease activity (MDA) domains through week 48 in adults with active psoriatic arthritis (PsA) who previously had an inadequate response to one to two tumor necrosis factor inhibitors (TNFi-IR), according to new data
- News You Can Use: AARS Launches Social Media Toolkit for #Acne Awareness Monthhttps://practicaldermatology.com/news/aars-launches-social-media-toolkit-for-acne-awareness-month/2461754/The American Acne and Rosacea Society (AARS) has launched a social media toolkit to help dermatology medical professionals who are their members share #acnefacts in recognition of Acne Awareness Month in June, The toolkit is available at acneandrosacea.org/acne-awareness-social- me
- Sun Pharma’s Ilumetri (Tildrakizumab Injection) Scores Nod For Plaque Psoriasis in Chinahttps://practicaldermatology.com/news/sun-pharmas-ilumetri-tildrakizumab-injection-scores-nod-for-plaque-psoriasis-in-china/2461753/The New Drug Application (NDA) of tildrakizumab injection under the brand name of Ilumetri has been approved by the National Medical Products Administration of the People’s Republic of China, Sun Pharma reports. Ilumetri is indicated for the treatment of adults wit
- Sun Pharma, Philogen Enter Into an Exclusive Distribution, License, and Supply Agreement for Nidlegy in Europe, Australia, and New Zealandhttps://practicaldermatology.com/news/sun-pharma-philogen-enter-into-an-exclusive-distribution-license-and-supply-agreement-for-nidlegy-in-europe-australia-and-new-zealand/2461752/Sun Pharmaceutical Industries has entered into a licensing agreement for commercializing Philogen’s Nidlegy (Daromun) in the territories of Europe, Australia and New Zealand. Nidlegy, currently in Phase III clinical trials, is a new anti-cancer biopharmaceutical which is bei
- Castle Biosciences Gives Back for Skin Cancer Awareness Monthhttps://practicaldermatology.com/news/castle-biosciences-gives-back-for-skin-cancer-awareness-month/2461750/Castle Biosciences, Inc. is teaming up with The Sun Bus and The Skin Cancer Foundation to support skin cancer prevention, research, education and advocacy. “At our core, we are passionate about transforming disease management, improving health and making a meaningful difference in